Literature DB >> 27648124

Invasive ductal carcinoma with in situ pattern: how to avoid this diagnostic pitfall?

Narasimhamurthy Mohan1, Jennifer O Black2, Mary R Schwartz3, Qihui Jim Zhai4.   

Abstract

Although the microscopic features of invasion are usually readily recognized, occasionally invasive ductal carcinoma may mimic the pattern of comedo ductal carcinoma in situ (DCIS) by forming large cellular nests with circumscribed borders, but lacking a definitive myoepithelial cell layer. In these cases, the histologic pattern may appear deceptively noninvasive and the absence of a myoepithelial layer can be easily overlooked. We prospectively examined 10 cases of high grade DCIS. P63, smooth muscle actin, muscle specific actin and calponin immunohistochemical stains were used to identify the presence of myoepithelial cells. In our study, 20% of apparent high grade DCIS cases did not exhibit a myoepithelial layer surrounding large, solid nests with comedo necrosis. Since invasion is defined by the absence of a myoepithelial layer, these results suggest that a DCIS-like pattern may actually represent invasive disease in some cases. Immunohistochemical studies may be essential in making this distinction and in avoiding the potential diagnostic pitfall.

Entities:  

Keywords:  Invasion; ductal carcinoma in situ; immunohistochemical stain; invasive ductal carcinoma; myoepithelial cells

Year:  2016        PMID: 27648124      PMCID: PMC5009386     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  22 in total

1.  Filament disassembly and loss of mammary myoepithelial cells after exposure to lambda-carrageenan.

Authors:  J K Tobacman
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

Review 2.  Proteolytic enzymes in cancer invasion and metastasis.

Authors:  R H Goldfarb; L A Liotta
Journal:  Semin Thromb Hemost       Date:  1986-10       Impact factor: 4.180

3.  Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.

Authors:  P Mignatti; E Robbins; D B Rifkin
Journal:  Cell       Date:  1986-11-21       Impact factor: 41.582

Review 4.  Use of immunohistochemistry in diagnosis of breast epithelial lesions.

Authors:  Rohit Bhargava; David J Dabbs
Journal:  Adv Anat Pathol       Date:  2007-03       Impact factor: 3.875

5.  The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.

Authors:  Jonathan F Lara; Steven M Young; Rowena E Velilla; Elissa J Santoro; Sandra F Templeton
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

6.  Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.

Authors:  Justin B Hilson; Stuart J Schnitt; Laura C Collins
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

7.  Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.

Authors:  Robert W Werling; Harry Hwang; Hadi Yaziji; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

Review 8.  Current management of ductal carcinoma in situ.

Authors:  A Barth; R J Brenner; A E Giuliano
Journal:  West J Med       Date:  1995-10

9.  Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition.

Authors:  Thorarinn Gudjonsson; Lone Rønnov-Jessen; René Villadsen; Fritz Rank; Mina J Bissell; Ole William Petersen
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

10.  A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers.

Authors:  Roy R Zhang; Yan-Gao Man; Russell Vang; Jeffrey S Saenger; Ross Barner; Darren T Wheeler; Chang Y Liang; Tuyethoa N Vinh; Gary L Bratthauer
Journal:  Breast Cancer Res       Date:  2003-07-24       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.